U.S. Food and Drug Administration (FDA) has approved the new broad-spectrum antibiotic, Paqflor® from Phibro Animal Health Corporation. Paqflor, is a 50% florfenicol premix, for use in salmonids, catfish, and tilapia. The product is designed to help control multiple bacterial diseases prevalent in freshwater aquaculture.
The product is designed to help control multiple bacterial diseases prevalent in freshwater aquaculture, including furunculosis, coldwater disease, columnaris, enteric septicaemia, and streptococcal septicaemia.
Mike Brown, Phibro’s vice-president of mineral nutrition and aqua in North America, said,
“We are excited to further support the US aquaculture industry’s efforts to reach its production and sustainability goals by bringing to market a proven, cost-effective, florfenicol antimicrobial product.”
He added that by bringing Paqflor to market, Phibro is giving producers more health management options.
“We share our customers’ commitment to improving productivity through good health management practices.â€
Paqflor is administered at a rate of 10 to 15 mg/kg of fish body weight daily over a 10-day period, offering flexibility and efficacy in managing disease across a range of warm and coldwater fish species.
Todd Armstrong, Phibro’s president in North America, said,
“Having a new aquaculture product in the US allows Phibro to continue our mission of providing safe and effective solutions for our customers’ unique health challenges.â€
More info: https://www.pahc.com/product_services/aqua/
